Format

Send to

Choose Destination
Ann Clin Biochem. 2016 Sep;53(Pt 5):561-7. doi: 10.1177/0004563215614036. Epub 2015 Oct 20.

Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2.

Author information

1
Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center, Goyang-si, South Korea.
2
Center for Uterine Cancer, and Gynecologic Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si, South Korea.
3
Biometric Research Branch, Research Institute and Hospital of National Cancer Center, Goyang-si, South Korea.
4
Center for Uterine Cancer, and Gynecologic Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang-si, South Korea Radiation Medicine Branch, Research Institute and Hospital, National Cancer Center, Goyang-si, South Korea.
5
Department of Laboratory Medicine and Hematologic Malignancy Branch, Research Institute and Hospital, National Cancer Center, Goyang-si, South Korea mindcatch@ncc.re.kr.

Abstract

BACKGROUND:

Anyplex II HPV HR (Anyplex_HR; Seegene, Seoul, Korea) is a new multiplex real-time polymerase chain reaction assay for screening cervical cancer, and it is designed to detect 14 high-risk human papillomaviruses along with all the genotype information in a single tube. The aim of this study was to evaluate the performance of the Anyplex_HR in comparison to that of the Cobas 4800 HPV (Cobas_4800; Roche Molecular Diagnostics, Pleasanton, CA, USA) and the Hybrid capture 2 (HC2; Qiagen GmbH, Hilden, Germany).

METHODS:

The performance of the Anyplex_HR for high-risk human papillomavirus genotype detection was prospectively evaluated against that of the HC2 and the Cobas_4800 at the National Cancer Center using 400 cervical samples. All discrepant samples were confirmed by polymerase chain reaction with type-specific primers followed by sequencing.

RESULTS:

The overall agreement and kappa value of the Anyplex_HR with the Cobas_4800 were 98.0% and 0.96, respectively. The level of agreement between the two assays and the corresponding kappa values for human papillomavirus16, human papillomavirus18 and other high-risk human papillomaviruses were 99.5%, 99.8% and 98.8%, and 0.98, 0.96 and 0.97, respectively. The agreement and kappa value of the HC2 with the Cobas_4800 were 95.3% and 0.91. The human papillomavirus positivity of the Anyplex_HR and the Cobas_4800 in low-grade squamous intraepithelial lesion/high-grade squamous intraepithelial lesion samples demonstrated 100% concordance. Both the Anyplex_HR and the Cobas_4800 showed excellent results in the precision test.

CONCLUSIONS:

The Anyplex_HR is comparable with the Cobas_4800 and the HC2 for human papillomavirus DNA testing, and it may prove more useful for follow-up testing and patient management by providing genotyping information additional to human papillomavirus16 and human papillomavirus18.

KEYWORDS:

DPO; Human papilloma virus; cervical cancer screening; performance evaluation; real-time PCR

PMID:
26486441
DOI:
10.1177/0004563215614036
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center